Letter | Published:

IL-23 promotes tumour incidence and growth

Nature volume 442, pages 461465 (27 July 2006) | Download Citation



Chronic inflammation has long been associated with increased incidence of malignancy and similarities in the regulatory mechanisms have been suggested for more than a century1. Infiltration of innate immune cells, elevated activities of matrix metalloproteases and increased angiogenesis and vasculature density are a few examples of the similarities between chronic and tumour-associated inflammation2. Conversely, the elimination of early malignant lesions by immune surveillance, which relies on the cytotoxic activity of tumour-infiltrating T cells or intra-epithelial lymphocytes, is thought to be rate-limiting for the risk to develop cancer3. Here we show a molecular connection between the rise in tumour-associated inflammation and a lack of tumour immune surveillance. Expression of the heterodimeric cytokine interleukin (IL)-23, but not of its close relative IL-12, is increased in human tumours. Expression of these cytokines antagonistically regulates local inflammatory responses in the tumour microenvironment and infiltration of intra-epithelial lymphocytes. Whereas IL-12 promotes infiltration of cytotoxic T cells, IL-23 promotes inflammatory responses such as upregulation of the matrix metalloprotease MMP9, and increases angiogenesis but reduces CD8 T-cell infiltration. Genetic deletion or antibody-mediated elimination of IL-23 leads to increased infiltration of cytotoxic T cells into the transformed tissue, rendering a protective effect against chemically induced carcinogenesis. Finally, transplanted tumours are growth-restricted in hosts depleted for IL-23 or in IL-23-receptor-deficient mice. Although many strategies for immune therapy of cancer attempt to stimulate an immune response against solid tumours, infiltration of effector cells into the tumour tissue often appears to be a critical hurdle4,5,6,7. We show that IL-23 is an important molecular link between tumour-promoting pro-inflammatory processes and the failure of the adaptive immune surveillance to infiltrate tumours.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    & Inflammation and cancer: back to Virchow? Lancet 357, 539–545 (2001)

  2. 2.

    & Inflammation and cancer. Nature 420, 860–867 (2002)

  3. 3.

    , & The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21, 137–148 (2004)

  4. 4.

    & Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses. Nature Rev. Cancer 2, 409–419 (2002)

  5. 5.

    & Cancer immunotherapy: a treatment for the masses. Science 305, 200–205 (2004)

  6. 6.

    , , , & Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol. 24, 335–342 (2003)

  7. 7.

    , & Mini-review: overcoming tumor-intrinsic resistance to immune effector function. Eur. J. Immunol. 34, 2635–2641 (2004)

  8. 8.

    et al. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol. Rev. 202, 96–105 (2004)

  9. 9.

    et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13, 715–725 (2000)

  10. 10.

    et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R. J. Immunol. 168, 5699–5708 (2002)

  11. 11.

    et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nature Immunol. 6, 1123–1132 (2005)

  12. 12.

    , , , & Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278, 1910–1914 (2003)

  13. 13.

    et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421, 744–748 (2003)

  14. 14.

    et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201, 233–240 (2005)

  15. 15.

    et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 101, 2620–2627 (2003)

  16. 16.

    , , , & Induction of expression of genes encoding components of the respiratory burst oxidase during differentiation of human myeloid cell lines induced by tumor necrosis factor and gamma-interferon. Cancer Res. 52, 2530–2537 (1992)

  17. 17.

    et al. The distinct contributions of murine T cell receptor (TCR)γδ+ and TCRαβ+ T cells to different stages of chemically induced skin cancer. J. Exp. Med. 198, 747–755 (2003)

  18. 18.

    et al. Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17. Immunity 22, 285–294 (2005)

  19. 19.

    et al. Autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor in human gliomas with tumor progression. Am. J. Pathol. 155, 1557–1567 (1999)

  20. 20.

    , , & MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103, 481–490 (2000)

  21. 21.

    et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biol. 2, 737–744 (2000)

  22. 22.

    Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nature Rev. Immunol. 3, 133–146 (2003)

  23. 23.

    et al. Antitumor and antimetastatic activity of IL-23. J. Immunol. 171, 600–607 (2003)

  24. 24.

    et al. Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res. 62, 3395–3401 (2002)

  25. 25.

    et al. IL-23 provides a limited mechanism of resistance to acute toxoplasmosis in the absence of IL-12. J. Immunol. 173, 1887–1893 (2004)

  26. 26.

    et al. IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-γ responses if IL-12p70 is available. J. Immunol. 175, 788–795 (2005)

  27. 27.

    et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. 199, 125–130 (2004)

  28. 28.

    , & A subset of skin tumor modifier loci determines survival time of tumor-bearing mice. Proc. Natl Acad. Sci. USA 96, 15032–15037 (1999)

  29. 29.

    , , & Characteristics of chemically transformed mouse epidermal cells in vitro and in vivo. Bull. Cancer 65, 271–279 (1978)

  30. 30.

    et al. Interleukin-12 is required for interferon-gamma production and lethality in lipopolysaccharide-induced shock in mice. Eur. J. Immunol. 25, 672–676 (1995)

Download references


We thank C. Strader for her comments on the manuscript. Author Contributions J.L.L. and X.Z. contributed equally to this work.

Author information

Author notes

    • John L. Langowski
    •  & Xueqing Zhang

    *These authors contributed equally to this work


  1. Schering-Plough BioPharma (formerly DNAX Research, Inc.), 901 California Avenue, Palo Alto, California 94304, USA

    • John L. Langowski
    • , Xueqing Zhang
    • , Lingling Wu
    • , Jeanine D. Mattson
    • , Taiying Chen
    • , Kathy Smith
    • , Beth Basham
    • , Terrill McClanahan
    • , Robert A. Kastelein
    •  & Martin Oft


  1. Search for John L. Langowski in:

  2. Search for Xueqing Zhang in:

  3. Search for Lingling Wu in:

  4. Search for Jeanine D. Mattson in:

  5. Search for Taiying Chen in:

  6. Search for Kathy Smith in:

  7. Search for Beth Basham in:

  8. Search for Terrill McClanahan in:

  9. Search for Robert A. Kastelein in:

  10. Search for Martin Oft in:

Competing interests

Reprints and permissions information is available at npg.nature.com/reprintsandpermissions. The authors declare no competing financial interests.

Corresponding author

Correspondence to Martin Oft.

Supplementary information

PDF files

  1. 1.

    Supplementary Notes

    This file contains Supplementary Figures 1–8 and the Supplementary Methods.

About this article

Publication history






Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.